Navigation Links
Altheus Therapeutics Secures $3.6 Million in Venture Capital
Date:9/18/2007

Biomedical start-up will fund clinical trials of its treatment for

inflammatory bowel disease.

OKLAHOMA CITY, Sept. 18 /PRNewswire/ -- Altheus Therapeutics, Inc. has secured $3.6 million in venture capital financing to fund clinical trials testing the efficacy of its therapy for the treatment of inflammatory bowel disease. St Louis-based Prolog Ventures led the round and was joined by the Oklahoma Seed Capital Fund and Oklahoma Equity Partners.

About 1.2 million Americans suffer from inflammatory bowel disease. The two most common forms, ulcerative colitis and Crohn's Disease, are chronic lifelong conditions which significantly impact the quality of life. Current therapies are reportedly effective less than 50% of the time.

The Altheus therapy combines two FDA approved drugs in a novel way and has been shown to be highly effective in animal models. This therapeutic approach is based on the research of Dr. Richard Harty, Emeritus Chief of Gastroenterology at the University of Oklahoma Health Sciences Center.

"We are very enthusiastic about our investment in Altheus, which allows the company to conduct the clinical trials needed to prove its product," said Brian Clevinger, founder and managing director at Prolog Ventures. "The initial data that Altheus has gathered is quite compelling. This is one of the most exciting companies we have seen in our pursuit of early-stage life science opportunities."

"This funding provides us with the capital to move our drug candidates forward into clinical trials," said Adam Payne, CEO of Altheus. "Our initial animal data suggest that our mechanistic approach is far superior to conventional frontline strategies -- which, if proven in the clinic, will provide a significant step forward for treatment. Conventional therapies can take as long as eight weeks to develop a clinical response. Our therapy may cut this time in half and help a larger portion of the population that
'/>"/>

SOURCE Altheus Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. TrafficCast secures $2M from Phenomenelle Angels, NEW Capital Fund
3. Perscitus Biosciences secures $250K Commerce loan
4. ProCertus BioPharm secures $2.3M in financing
5. Mirus Bio secures $900K grant to develop research tool
6. BioSystem Development secures angel funding
7. TrafficCast secures $1 million line of credit
8. Medical College secures $9.7M research grant
9. Wausau start up secures $560K for GPS maps
10. Platypus Technologies secures $450K SBIR grant
11. nPoint Secures Second Round of Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited (ASX:BNO, ... DisrupTOR-1 trial of BNC105 in patients with metastatic renal ... Orlando, Florida . The data will be ... City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 as ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Steep Hill, ... the US and internationally, intends to open a full ... Albuquerque, New Mexico , bringing advanced scientific tools ... cannabis. Steep Hill is currently the only ... to conduct potency and contaminant testing in order to ...
(Date:2/26/2015)... 2015  23andMe, the leading personal genetics company, today ... Privacy Officer and Corporate Counsel. Black brings a strong ... well as health care regulations. As a member of ... for reviewing, updating and enhancing the company,s privacy and ... She joined the company January 5, 2015 and reports ...
(Date:2/26/2015)... Protiviti ( www.protiviti.com ), a global consulting ... Governance Portal , designed to increase the efficiency with ... across multiple business units and projects. The Governance Portal ... align their controls with the COSO ( Committee of ... response to client feedback, Protiviti has also included a ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 223andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3
... Hospitals and Public Health Care ... ... effort to help government,entities, hospitals and public health care agencies be ... industry about the proper storage and handling of vaccine,materials. In order ...
... Outreach to Commence, LA JOLLA, Calif., ... Board: TDLP),( http://www.transdelpharma.com ) (the "Company"), a ... non-invasive, topically,administered medications, has retained the Investor ... communications,firm based in New York City, to ...
... England, November 10 , - ("Stem Cell ... plc (AIM:STEM, ASX:STC), a company focused on the,commercialisation ... that,it has entered into an agreement with CHDI ... mouse embryonic stem (ES) cell lines. CHDI,is a ...
Cached Biology Technology:Sentry Logistic Solutions Offers Outsourced Vaccine Storage & Distribution Service 2Sentry Logistic Solutions Offers Outsourced Vaccine Storage & Distribution Service 3Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group 2Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group 3Stem Cell Sciences Enters into Services Agreement with Huntingdon's Disease Research Group, CHDI Foundation Inc. 2Stem Cell Sciences Enters into Services Agreement with Huntingdon's Disease Research Group, CHDI Foundation Inc. 3Stem Cell Sciences Enters into Services Agreement with Huntingdon's Disease Research Group, CHDI Foundation Inc. 4
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication company ... of the Wocket™ smart wallet at CES 2015 in Las ... one of the "11 Hot Products at CES" in a review published ... Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small Cap ... report showed that planet-wide, transactions at merchants on the leading ... total number of credit, debit, and prepaid cards reached 6.54 ... victims of fraudulent card usage in 2012, and credit and ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... to contain and treat is its rapid evolution. Understanding how ... vital. , Host cells produce two proteins that mutate HIV ... HIV produces a protein, called Vif, that can disable the ... in sequence and in function, according to a new study ...
... nutrition on blood disease porphyria , Dana-Farber Cancer Institute ... the episodic attacks of irrational and demented behavior in ... George III, the British ruler blamed for the loss ... The mental and physical symptoms of porphyria, a rare ...
... first time, physicians at University Health Network and University ... that can predict whether a patient with chronic Hepatitis ... , These genes could also become the basis of ... which patients will respond to therapy. , The study, ...
Cached Biology News:Attacks of King George III's madness linked to key metabolism molecule 2Attacks of King George III's madness linked to key metabolism molecule 3Identification of specific genes predicts which patients will respond to Hepatitis C treatment 2Identification of specific genes predicts which patients will respond to Hepatitis C treatment 3
AVOID FREEZE/THAW CYCLES. Recognizes the UCP-2 protein....
Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
MAb to HSV-2, gG-2 HSV-2 Glycoprotein G-2...
Immunogen for A300-655A was a phosphorylated synthetic peptide, which represented a portion of human RNA Polymerase II (GeneID 5430) around serine 5 of the C-terminal repeat YSPTSPS....
Biology Products: